Le Lézard
Classified in: Health
Subjects: SVY, CFG, MAT

Health Canada releases new data on cannabis use in Canada


The 2023 Canadian Cannabis Survey provides important insights into Canadians' knowledge, attitudes and behaviours on cannabis use

OTTAWA, ON, Jan. 12, 2024 /CNW/ - Today, Health Canada published the results of the 2023 Canadian Cannabis Survey (CCS). The data was collected from May 2 to July 20, 2023. This is the seventh cycle of the Canadian Cannabis Survey, which Health Canada has conducted every year since 2017.

The Government of Canada collects data to better understand how Canadians view and use cannabis. Through the collection of this data, we can better monitor Canada's national framework for controlling the production, distribution, sale and possession of cannabis under the Cannabis Act.

Key findings from the 2023 Canadian Cannabis Survey include:

The results from the Canadian Cannabis Survey will help Health Canada better understand habits and behaviours relative to cannabis use over time and will support the development of policy and program initiatives, including public education and awareness activities. The data from the survey will also help to inform the legislative review of the Cannabis Act, which is being led by an independent expert panel.

Quick Facts
Related Products
Associated Links

SOURCE Health Canada (HC)


These press releases may also interest you

at 18:12
The global functional food ingredients market size is estimated to grow by USD 53.14 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 7.38% during the forecast period. ...

at 17:55
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:25
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...



News published on and distributed by: